Categories: EHRNewsPharmaceutical

Travere Therapeutics to Report Second Quarter 2023 Financial Results

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2023 financial results on Thursday, August 3, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

The webcast and dial-in information can be accessed on the Investor page of Travere’s website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Investors: Media:
Naomi Eichenbaum Nivi Nehra
Vice President, Investor Relations Vice President, Corporate Communications
888-969-7879 888-969-7879
ir@travere.com mediarelations@travere.com

Staff

Recent Posts

Zepbound Coupons and Discounts From Duty Free Meds

Duty Free Meds is proud to introduce a new Zepbound coupon offering to help lower…

1 hour ago

Zepbound Coupons and Discounts From Duty Free Meds

Duty Free Meds is proud to introduce a new Zepbound coupon offering to help lower…

1 hour ago

Rising From the Ashes: Ivy en Rose MedSpa Reopens in San Francisco, Exemplifying Strength and Community Spirit

Beloved MedSpa Overcomes Devastating Fire and Challenges to Continue Serving the Bay Area SAN FRANCISCO,…

1 hour ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company’s Pipeline Development

MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage…

1 hour ago